"Biocatalysis is an evolving success story in the industry,” says Alice Dunbabin, Senior Scientist at CatSci, in this month’s issue of The Medicine Maker. But what factors are contributing to the popularity of this process? You can find Alice’s opinion below along with articles on the importance of analytical testing for vaccine development and the growth of the immunology sector. We also sit down with Sandy Macrae, Chief Executive Officer, Sangamo Therapeutics, USA, who explains why leadership is both an art and a science.
 
ADVANCED MEDICINE
Of Plumbing and Poetry
02/04/2021 | James Strachan
We Sit Down With Sandy Macrae, Chief Executive Officer, Sangamo Therapeutics, USA.
BUSINESS PRACTICE
Crafting a Culture of Excellence
01/12/2021 | Maryam Mahdi
Sitting down with Janssen's David Lee to discuss a new era in immunology R&D.
COVID-19
Better Methods for Better Vaccines
01/18/2021 | Ewoud van Tricht
Ewoud van Tricht explores three novel methods that could streamline the development of adenovirus vaccines for COVID-19 at Janssen.
SMALL MOLECULES
Are You a Bio-Catalytic Converter?
02/09/2021 | Alice Dunbabin
Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.
 
White Paper
Discover the importance of early form screening in JM's insightful white paper

JM offers leading solid state services through their experience in solid form screening and particle engineering. Discover unique insights into the importance of understanding the form of an API. Read more
Exploring the rigor and requirements of Analytical Quality by Design

Analytical QbD (AQbD) promises to extend the rigor and benefits of QbD into the area of analytical method development. Read more
How to characterize Magnetically Tunable Colloidal Photonic Crystals easily and quickly

Recently, a magnetically tuneable photonic crystal system has been developed by assembling highly charged Fe3O4 colloidal nanocrystal clusters (CNCs) [1,2]. Read more
 
Product Profiles
OneXpress™ Solution for Accelerating Development to Commercialization

Catalent’s new OneXpress™ solution combines phase-appropriate scale and technologies with expertise across diverse dose forms to accelerate a program’s development to commercialization. Read more
The first ever human trial of a nanoformed drug

Nanoform has partnered with Quotient Sciences to start the first ever human trial of a drug candidate nanoformed using its CESS® technology, opening up exciting possibilities for the future of medicine. Read more
 
Special Promotions
Facing the COVID-19 Crisis: Leadership and the Future of Pharma

We brought together an expert panel of Power List winners to discuss the impact of COVID-19 on the industry, the challenges of leadership during the pandemic, and the lessons the pharma industry must learn as a whole from the crisis. Hear what they have to say here
Help us measure “Pandemic Impact” in Biopharma for a chance to win $100!

Take the “Pandemic Impact: Biopharma Trends 2021 Survey” now and you could win a $100 Amazon voucher (or a charitable donation, if preferred). Start Survey
 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.
Find out more
This email was sent to {~email~} by info@themedicinemaker.com. To ensure delivery of emails to your inbox, please add info@themedicinemaker.com to your address book or safe sender list. To view online, please click here.

Create or manage your account here
Unsubscribe here

The Medicine Maker is a brand of Texere Publishing Limited (trading as Conexiant)

Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.